Current treatment status-Not currently treated Posts on Medivizor
Navigation Menu

Current treatment status-Not currently treated Posts on Medivizor

Looking for patients with relapsed or unresponsive multiple myeloma to test a new antibody drug

Posted by on Aug 14, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment.  The details Both multiple myeloma (MM) and non-Hodkin lymphoma...

Read More

Looking for patients with BRAF positive inoperable colorectal cancer to test a new treatment combination

Posted by on Aug 14, 2019 in Colorectal cancer | 0 comments

In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...

Read More

Evaluating BCD chemotherapy for patients with peripheral T-cell lymphoma

Posted by on Jul 31, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of BCD chemotherapy (bendamustine, carboplatin, and dexamethasone) for patients with peripheral T-cell lymphoma that has come back or stopped responding to treatment. This study concluded that this treatment was promising, with minimal side effects. Some background Peripheral T-cell...

Read More

Searching for patients to try a new therapy for advanced solid tumors.

Posted by on Jul 24, 2019 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...

Read More

Quizartinib in the treatment of relapsed or unresponsive acute myeloid leukemia

Posted by on Jul 14, 2019 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of quizartinib compared to chemotherapy in the treatment of relapsed or unresponsive acute myeloid leukemia (AML). Researchers found that quizartinib was safer and more effective than chemotherapy in these patients. Some background Acute myeloid leukemia (AML) is a cancer of the bone...

Read More

Searching for patients with unresponsive cancer to test a new treatment

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers.  The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...

Read More

Searching for patients with recurrent or non-responsive lymphoma to try this new treatment option

Posted by on Jun 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...

Read More